UJI TOKSISITAS SUBKRONIS EKSTRAK CURCUMA BEBAS MINYAK ATSIRI (ECBA) DITINJAU DARI PARAMETER PROFIL LEUKOSIT PADA TIKUS PUTIH GALUR WISTAR
DOI:
https://doi.org/10.12928/pharmaciana.v4i1.398Keywords:
Ekstrak Curcuma Bebas Minyak Atsiri, curcumin, toxicity, leukocytesAbstract
The effect of Volatil Oil of Curcuma Extraxt or Curcumin extract with
centration of essential oil in reducing the levels of cholesterol in the blood has been
ECBA as antihyperlipidemic agent is given for a long - term therapeutic purpose. This
experiment was performed to investigate the subchronic toxicity of ECBA on leukocytes profile of
Wistar rats. ECBA was investigated at dose 15 mg, 120 mg, and 960 mg/200 g body weight for 90
days in 40 male Wistar rats. CMC-Na was used for control. The blood was examined for the
leukocytes profile on day 0, 45, and 90. The rats were still maintained under experimental conditions
without giving ECBA until day 105 for the reversibility test. The result showed that the administration
of ECBA for 90 days did not affect leukocytes profile of Wistar rats.
Downloads
Published
Issue
Section
License
Authors who publish with Pharmaciana agree to the following terms:
- Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.